The Non-Financial Ledger: What Dollar Amounts Cannot Measure

Imagine you’re sitting in a doctor’s office. You’ve just been told you have Alzheimer’s. You’ve just been told your mother has Parkinson’s. You’ve just been handed a diagnosis of cancer and you don’t know what to do next. You are terrified, and you are looking for anything that might help, anything that sounds credible, anything that promises relief.

Kushly Industries found you. Their marketing, at some point between May 2019 and August 2020, reached you and told you their CBD products could help. Maybe it said “treats cancer.” Maybe it said “helps with Alzheimer’s disease.” Maybe it positioned their oil or capsule as something that could ease the suffering of multiple sclerosis, or quiet the disorder of bipolar disorder, or bring back some peace to someone drowning in PTSD. The FTC’s own complaint confirms these were the conditions Kushly made claims about. Not hypothetically. By name.

There is a specific kind of betrayal that happens when you are medically vulnerable and someone sells you false hope. It is different from being tricked on a consumer product. It operates at the level of your fear. It costs you money you spent on a product that did nothing clinically proven to help you. But the damage that doesn’t get counted in the $30,583.14 penalty is the decision you made instead of something that might have actually helped. The specialist appointment you postponed because you thought you had something working. The medication you skipped a refill on. The conversation you had with a dying family member where you said, “I found something.”

Kushly’s marketing reached people dealing with anorexia nervosa, a condition with the highest mortality rate of any psychiatric disorder. It made claims about psychosis. It targeted people with obsessive-compulsive disorder, panic disorder, and social anxiety disorder. These are people whose relationship with reality, with safety, with their own bodies was already fragile. They were sold certainty by a company that, per the FTC’s findings, had no scientific evidence to back a single claim.

The FTC’s own mandatory customer notice, the letter Cody Alt had to sign and mail, explicitly warns those customers: “CBD products could be dangerous if you take them with other medicines or at a high dose. They also could interfere with other medications you’re taking or treatments you’re getting.” That warning, buried at the bottom of the required disclosure letter, is the company confirming that its own products may have actively harmed the people it claimed to be helping. The harm is not theoretical. It came from inside the marketing itself.

The settlement covers eligible customers who bought between May 26, 2019 and August 27, 2020. Those customers will receive some fraction of $30,583.14, divided among all of them. If even 300 people bought during that period, they receive about $100 each. For someone who bought CBD products to treat cancer or Parkinson’s disease, $100 does not touch what they were put through.

Legal Receipts: What the Documents Actually Say

The FTC’s consent order and the mandatory customer notification letter are the primary sources here. These are not summaries or editorials. They are the government’s documented findings and the company’s court-required admissions. Every quote below comes directly from those documents.

“The FTC says we do not have scientific evidence that our CBD products can treat or cure diseases and health conditions including sleep disorders like insomnia and narcolepsy; psychiatric disorders like depression, bipolar disorder, post-traumatic stress disorder, psychosis, and anorexia nervosa; diseases and conditions like cancer, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, and hypertension; skin conditions like acne, psoriasis, and eczema; and pain associated with arthritis, endometriosis, and menstruation (dysmenorrhea).” Source: Attachment A to the FTC Order, the mandatory customer notification letter, signed by Cody Alt, CEO, Kushly Industries LLC

• This is not a paraphrase. This is the exact language Cody Alt was legally required to put in his own name and send by first-class mail to every customer who bought his products during the covered period. He personally signed this admission.
• The list of conditions Kushly claimed to address without scientific backing is not a handful of minor complaints. It includes cancer, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, psychosis, and anorexia nervosa. These are life-altering and life-threatening diagnoses.
• The phrase “we do not have scientific evidence” is the company confirming the FTC’s core finding: the marketing claims were made without the required proof. The deception was the gap between the claim and the evidence.

“The FTC says we do not have scientific evidence that our CBD products can help muscles heal fast. The FTC says studies do not prove that our CBD products treat or cure any of the diseases and health conditions listed above.” Source: Attachment A to the FTC Order, mandatory customer notification letter

• This confirms Kushly’s claims extended beyond the disease framework. The company also marketed its products to athletes or physically active consumers with claims about muscle recovery, again without scientific substantiation.
• The phrase “studies do not prove” is the FTC’s hard line: it is not that the evidence was weak or contested. It is that the evidence to support these claims, as required by law, did not exist.

“Respondents, Respondents’ officers, agents, employees, and attorneys, and all other persons in active concert or participation with any of them… must not make, or assist others in making, expressly or by implication, any representation that such Covered Product effectively treats, mitigates, or cures diseases or health conditions including… cancer… Alzheimer’s disease… Parkinson’s disease… unless the representation is non-misleading, and, at the time of making such representation, they possess and rely upon competent and reliable scientific evidence that substantiates that the representation is true.” Source: FTC Order Provision I, Prohibited Representations: Regarding Health-Related Claims Requiring Human Clinical Testing For Substantiation

• This provision exists precisely because Kushly was making these representations without the required evidence. The order did not invent a new standard; it enforced the standard Kushly was already required to meet and didn’t.
• The phrase “or by implication” is significant. The FTC is covering not just explicit false claims but the entire architecture of marketing suggestion, including imagery, testimonials, and product naming strategies that imply therapeutic benefit without stating it directly.
• The requirement going forward is specific: randomized, double-blind, placebo-controlled human clinical testing. That is pharmaceutical-grade proof. Kushly was selling products requiring that level of proof and had none of it.

“Respondents must notify all affiliates or other resellers who either (1) purchased CBD Products from Respondents or (2) sold, distributed, or promoted CBD Products on behalf of Respondents by sending each by first-class mail, postage paid and return receipt requested… a notification letter… Respondents must include a copy of this Order, but no other document or enclosure.” Source: FTC Order Provision X, Notice to Wholesalers, Affiliates, and Other Distributors

• This provision confirms Kushly operated through a network of affiliates, resellers, and distributors. The false claims were not confined to Kushly’s own website. They spread through third-party channels, multiplying the reach of the deception.
• The requirement to notify distributors with no other enclosure beyond the order itself is the FTC ensuring the order cannot be softened, reframed, or buried by Kushly when communicating with its own business partners.

“The facts alleged in the Complaint establish all elements necessary to sustain an action by or on behalf of the Commission pursuant to Section 523(a)(2)(A) of the Bankruptcy Code, 11 U.S.C. § 523(a)(2)(A), and this Order will have collateral estoppel effect for such purposes.” Source: FTC Order Provision VII(C)

• This is the FTC specifically closing the bankruptcy escape hatch. It means Cody Alt and Kushly Industries cannot discharge the financial obligations of this order by filing for bankruptcy. The debt survives bankruptcy under federal fraud provisions.
• The fact that the FTC included this provision signals that the Commission considered the possibility that the respondents might attempt to escape repayment via insolvency proceedings. This is a standard protective clause but its inclusion is telling about the context.

Timeline: From First Sale to Federal Order

The sequence of events documented in the FTC order reveals a company that operated with misleading health claims for over a year before federal intervention, and that the accountability process itself stretched well beyond the period of consumer harm.

What They Claimed vs. What the FTC Found

The gap between Kushly’s marketing claims and the scientific reality is the entire case. The FTC’s consent order names both the specific claims Kushly was making and the fact that none of them were backed by the required evidence at the time of making them.

Societal Impact Mapping: Who Gets Hurt When Supplement Companies Lie

Public Health

Kushly’s false claims created documented public health risk in two directions: they encouraged people with serious conditions to trust an unproven product, and they actively warned against drug interactions only after the FTC forced the company’s hand.

• The FTC’s mandatory customer notice confirms CBD can be “dangerous if you take them with other medicines or at a high dose” and “could interfere with other medications you’re taking or treatments you’re getting.” Kushly’s pre-order marketing made none of these disclosures while simultaneously encouraging use by people with active medical conditions.
• Kushly targeted patients with cancer, Alzheimer’s disease, and Parkinson’s disease with curative claims. People in these categories are frequently on complex pharmaceutical regimens. The intersection of undisclosed CBD drug interactions and serious disease pharmacology represents a direct public health hazard the FTC forced Kushly to acknowledge in writing only after intervention.
• The psychiatric conditions Kushly claimed to treat, including psychosis, PTSD, bipolar disorder, and anorexia nervosa, involve populations with elevated vulnerability to false hope claims. Anorexia nervosa carries the highest fatality rate of any psychiatric diagnosis. Marketing unproven treatments to this population, without evidence and without disclosing risks, is a harm that exists independent of whether any individual patient was documented as harmed in the consent order.
• The FTC’s prohibition requires that future health claims meet the standard of randomized, double-blind, placebo-controlled human clinical trials. This standard exists specifically because less rigorous evidence has repeatedly been shown to mislead both consumers and practitioners. Kushly operated below this standard for at least 15 months of documented sales.
• The customer notification order mandated that Kushly direct buyers to learn more at ftc.gov/miraclehealth, a federal resource specifically dedicated to combating fraudulent health product marketing. The FTC’s decision to route Kushly’s customers to that resource signals how it categorized this conduct: in the same category as known miracle-cure scam operations.

Economic Inequality

The economic structure of this case concentrates harm at the bottom of the income ladder while the regulatory penalty is too small to function as a meaningful deterrent against future operations.

• The total redress fund ordered is $30,583.14. This sum will be divided among every eligible customer who bought Kushly CBD products between May 26, 2019 and August 27, 2020. For each buyer, their recovery will be a fraction of what they paid, assuming they receive any payment at all after fund administration costs are deducted.
• CBD wellness products marketed as therapeutic are disproportionately purchased by people who cannot afford or cannot access the conventional medical system. Someone who buys a $40 CBD oil to manage their anxiety disorder, depression, or arthritis is often doing so because a doctor visit, a prescription, or a specialist costs money they do not have. Kushly’s marketing specifically reached people in that position and gave them false confidence in a substitute.
• The FTC’s consent order places compliance and recordkeeping obligations on Kushly for 10 years and prohibitions for 20 years. These are significant obligations, but they carry no financial sanction calibrated to the scale of potential profit from operating a CBD company during the height of the industry’s marketing boom (2019-2020). The $30,583.14 figure reflects available assets at settlement, not damages proportionate to consumer harm across 15 months of documented false advertising.
• The bankruptcy protection clause in the order (Provision VII(C)) exists because the FTC anticipated the possibility that Kushly or Cody Alt might attempt to discharge the financial obligations through insolvency. This clause protects the government’s claim, but it signals the limitations of the settlement’s economic teeth for ordinary consumers who have no equivalent legal protection in private disputes with the company.
• The redress process requires customers to be identifiable in Kushly’s own records. Consumers who paid in ways that were not tracked, who did not register accounts, or who were reached through third-party affiliates and resellers may never be identified as eligible, further shrinking the pool of people who receive any compensation at all.

The “Cost of a Life” Metric: What the Penalty Actually Means

What Now: The People Responsible and the Watchdogs Still on the Case

The FTC’s order names the specific individuals and entities with ongoing compliance obligations. These are the parties legally bound by the 20-year prohibition. Understanding who is responsible and which agencies retain oversight is the first step toward accountability.

Parties Bound by the Order

• Kushly Industries LLC: Arizona limited liability company, principal office at East Rancho Vista Drive, #3014, Scottsdale, Arizona 85251. Bound for 20 years under FTC Docket No. C-4749. Any successor company or reorganized entity takes on these obligations under Provision XII.
• Cody Alt, Owner, CEO, and Manager: Named individually as a respondent. His personal compliance obligations, including annual sworn compliance reports, address change notifications, and business activity disclosures, run for 10 years. His financial obligations survive any potential bankruptcy filing.
• All affiliates and resellers who sold Kushly CBD products are required to have received a copy of the order via certified mail. Any distributor who continues promoting Kushly products under the prior marketing claims is in direct violation of this order.

Regulatory Watchlist

• Federal Trade Commission (FTC): The primary enforcement body on this case. The FTC retains the right to use undercover compliance monitoring, posing as consumers, suppliers, or other entities, to verify compliance at any time without prior notice, under Provision XIV(C). File a complaint at ftc.gov/complaint.
• Food and Drug Administration (FDA): The FDA regulates labeling claims on CBD products as both dietary supplements and potential drugs. Any FDA-unapproved therapeutic claim on a CBD product remains an active regulatory concern. The order explicitly grants an exception only for FDA-approved claims.
• Federal Bankruptcy Court System: The collateral estoppel provision in the order means that if Cody Alt or Kushly Industries files for bankruptcy, any bankruptcy court must treat the FTC’s fraud findings as established fact. This is an active protective mechanism, not a theoretical one.
• State Attorneys General: State consumer protection offices in Arizona (Kushly’s home state) and any state where Kushly sold products retain independent authority to investigate and prosecute deceptive health marketing claims under state law, separate from the federal order.

What You Can Do: Mutual Aid and Grassroots Resistance

• If you bought Kushly CBD products between May 26, 2019 and August 27, 2020, you are an eligible customer under this order. The FTC was required to set up a dedicated phone number and email address for redress inquiries. Check ftc.gov for current consumer redress program status on Docket No. C-4749. Kushly was also required to post notice on kushly.com and all its social media accounts.
• Report any CBD company making specific disease claims without citing randomized, double-blind, placebo-controlled human clinical trial evidence directly to the FTC at ftc.gov/complaint. The standard established in this order applies to the entire industry. Claims that CBD “treats,” “cures,” or “mitigates” cancer, Alzheimer’s, Parkinson’s, depression, or any other named condition require pharmaceutical-grade proof. If a company is advertising those benefits right now, report it.
• Share this case with patient advocacy communities for Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, PTSD, and eating disorders. These communities are frequently targeted by unsubstantiated supplement marketing. The FTC’s documented findings in this case are a concrete, citable example of how that marketing operates and what it costs the people it deceives.
• Organize locally around pharmaceutical access: The reason CBD miracle-cure marketing finds an audience is that legitimate medical treatment is priced out of reach for millions of people. Advocacy organizations working on drug price reform, Medicaid expansion, and sliding-scale community health clinics directly address the conditions that make deceptive health product marketing profitable. Support them materially: show up, donate, volunteer, and vote for policies that reduce medical desperation.
• Demand the FTC raise penalty structures for health fraud cases: $30,583.14 for 15 months of false cancer and Alzheimer’s cure claims is a structural failure, not an oversight. Contact your congressional representatives through house.gov and senate.gov and ask them to support FTC penalty authority reforms that scale fines to the revenue generated by the deceptive conduct, not just available assets at settlement time.